Kees Jalink

Kees Jalink

Auto-generated profile, based on publicly available information

Kees Jalink

Division of Cell Biology The Netherlands Cancer Institute Amsterdam The Netherlands

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 1989 in Cell
Verified
Journal Article
Closed access
ECEmile J. van Corven
Emile J. van Corven
AGAlida Groenink
Alida Groenink
KJKees Jalink
Kees Jalink
TEThomas Eichholtz
Thomas Eichholtz
WMWouter H. Moolenaar
Wouter H. Moolenaar

23 March 2015 in Nature
Verified
Journal Article
Closed access
PDF file
GXGuotai Xu
Guotai Xu
JCJ. Ross Chapman
J. Ross Chapman
IBInger Brandsma
Inger Brandsma
JYJingsong Yuan
Jingsong Yuan
MMMartin Mistrik
Martin Mistrik
SRSven Rottenberg
Sven Rottenberg

1 May 1993 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
TET Eichholtz
T Eichholtz
KJK Jalink
K Jalink
IFI Fahrenfort
I Fahrenfort
WMW H Moolenaar
W H Moolenaar
Lysophosphatidic acid (LPA) is a water-soluble phospholipid with hormone-like and growth-factor-like activities. LPA activates a putative G-protein-coupled receptor in responsive cells, but the natural source of exogenous LPA is unknown. Here we show that LPA is present in mammalian serum in an active form (bound to albumin) at concentrations of 1-5 microM, but is not detectable in platelet-poor plasma, suggesting that LPA is produced during blood clotting. We find that thrombin activation of platelets prelabelled with [32P]Pi results in the rapid release of newly formed [32P]LPA into the extracellular environment. We conclude that LPA is a novel platelet-derived lipid mediator that may play a role in inflammatory and proliferative responses to injury.

1 August 1994 in Journal of Cell Biology
Verified
Journal Article
Open access
KJK Jalink
K Jalink
ECE J van Corven
E J van Corven
THT Hengeveld
T Hengeveld
NMN Morii
N Morii
SNS Narumiya
S Narumiya
WMW H Moolenaar
W H Moolenaar
Addition of the bioactive phospholipid lysophosphatidic acid (LPA) or a thrombin receptor-activating peptide (TRP) to serum-starved N1E-115 or NG108-15 neuronal cells causes rapid growth cone collapse, neurite retraction, and transient rounding of the cell body. These shape changes appear to be driven by receptor-mediated contraction of the cortical actomyosin system independent of classic second messengers. Treatment of the cells with Clostridium botulinum C3 exoenzyme, which ADP-ribosylates and thereby inactivates the Rho small GTP-binding protein, inhibits LPA- and TRP-induced force generation and subsequent shape changes. C3 also inhibits LPA-induced neurite retraction in PC12 cells. Biochemical analysis reveals that the ADP-ribosylated substrate is RhoA. Prolonged C3 treatment of cells maintained in 10% serum induces the phenotype of serum-starved cells, with initial cell flattening being followed by neurite outgrowth; such C3-differentiated cells fail to retract their neurites in response to agonists. We conclude that RhoA is essential for receptor-mediated force generation and ensuing neurite retraction in N1E-115 and PC12 cells, and that inactivation of RhoA by ADP-ribosylation abolishes actomyosin contractility and promotes neurite outgrowth.

1 September 2015 in Cell
Verified
Journal Article
Closed access
JKJop Kind
Jop Kind
LPLudo Pagie
Ludo Pagie
SVSandra S. de Vries
Sandra S. de Vries
LNLeila Nahidiazar
Leila Nahidiazar
SDSiddharth S. Dey
Siddharth S. Dey
BSBas van Steensel
Bas van Steensel

1 December 2004 in EMBO Reports
Verified
Journal Article
Open access
PDF file
BPBas Ponsioen
Bas Ponsioen
JZJun Zhao
Jun Zhao
JRJurgen Riedl
Jurgen Riedl
FZFried Zwartkruis
Fried Zwartkruis
GKGerard van der Krogt
Gerard van der Krogt
KJKees Jalink
Kees Jalink
Epac1 is a guanine nucleotide exchange factor for Rap1 that is activated by direct binding of cAMP. In vitro studies suggest that cAMP relieves the interaction between the regulatory and catalytic domains of Epac. Here, we monitor Epac1 activation in vivo by using a CFP–Epac–YFP fusion construct. When expressed in mammalian cells, CFP–Epac–YFP shows significant fluorescence resonance energy transfer (FRET). FRET rapidly decreases in response to the cAMP‐raising agents, whereas it fully recovers after addition of cAMP‐lowering agonists. Thus, by undergoing a cAMP‐induced conformational change, CFP–Epac–YFP serves as a highly sensitive cAMP indicator in vivo . When compared with a protein kinase A (PKA)‐based sensor, Epac‐based cAMP probes show an extended dynamic range and a better signal‐to‐noise ratio; furthermore, as a single polypeptide, CFP–Epac–YFP does not suffer from the technical problems encountered with multisubunit PKA‐based sensors. These properties make Epac‐based FRET probes the preferred indicators for monitoring cAMP levels in vivo .